Actively Recruiting
Comparing Shorter and Usual Radiation Therapy with Standard Chemotherapy for Muscle Invasive Bladder Cancer in the ARCHER Trial
Led by NRG Oncology · Updated on 2026-10-23
486
Participants Needed
259
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two different radiation therapy schedules combined with standard chemotherapy drugs for treating patients with muscle invasive bladder cancer. This phase III trial aims to compare the effectiveness of ultra-hypofractionated radiation therapy, which delivers higher radiation doses over a shorter period, against the usual hypofractionated radiation therapy. The study seeks to show that the shorter radiation schedule is not worse by more than 10% in bladder-intact event-free survival at 3 years, while also assessing side effects, patient quality of life, and biomarkers related to disease recurrence. Participants are randomly assigned to one of two treatment groups. One group receives hypofractionated radiation therapy once daily, Monday through Friday, for 20 treatments alongside one of three chemotherapy regimens chosen by their doctor weekly cisplatin for 4 weeks gemcitabine given on several specified days or weekly for 4 weeks or mitomycin-C plus fluorouracil over two separate 5-day periods. The other group receives ultra-hypofractionated radiation therapy once daily, no more than twice a week, for 5 treatments with the same chemotherapy options. During the study, all patients undergo imaging scans such as CT, MRI, or PET, and may optionally provide blood and urine samples and biopsies during follow-up. Throughout participation, patients are monitored with scans and laboratory tests, and their symptoms and quality of life are tracked. Follow-up visits occur at week 16 after treatment, then every 3 months for 2 years, and every 6 months up to 5 years. The study measures bladder-intact event-free survival as the primary outcome, as well as urinary and bowel side effects, overall survival, and circulating tumor DNA as a biomarker. Optional sample collections and biopsies help researchers understand disease recurrence and response to therapy over the long term.
CONDITIONS
Brief Title
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here